Close Menu

Cepheid

The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes. 

The company said it ultimately plans to use the liquidity from the credit facility to fund a portion of its pending $4 billion acquisition of Cepheid.

The $4 billion acquisition is now cleared in the US, Germany, Austria, and South Africa. 

The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.

The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.

Trichomonas is a nonviral sexually transmitted disease caused by infection with the protozoan parasite Trichomonas vaginalis.

Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.

The firm's reagents and disposables business was the biggest gainer, with a 12 percent revenue increase in the quarter. 

Pages

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.